| |
|
|
|
Oxford Global, Copthorne Tara hotel, Kensington, London, UK
22nd & 23rd April 2010
The pharmaceutical industry is facing rising clinical development costs and falling drug discovery success rates. In order to stay competitive, they are re-evaluating their drug development processes and working to reduce late phase attrition rates. The industry is investing more in safety and research measures than ever before and combined with an ever-changing framework of regulation the path the market has never been more complicated or costly for key practitioners in Drug Development. There is an urgent need for improved phase processes, Partnering and Outsourcing strategies and Novel Technologies that will enable the delivery of improved drugs to market quicker and ultimately the establishment of a more robust and lean pipeline.
The 2nd Annual Drug Development Summit 2010, presented by Oxford Global Conferences, will provide a first class educational and networking opportunity for over 120 attendees. Do not miss out on this opportunity to gain new insight on how to effectively manage and streamline your Early Development process. Over the 2 days, the summit will feature key note addresses, case study presentations, and panel discussions featuring over 40 senior level industry speakers from the leading pharmaceutical, biotechnology, diagnostics, clinical research and academic institutions, exploring the following hot topics:
Day One
Stream One:
Drug Safety: Studying the elevated role of drug safety and toxicology and the new techniques and technologies available, with reference
to case studies from multiple therapeutic areas.
Stream Two:
Regulation and Risk/Benefit Assessments: Exploring the latest regulation guidelines and global frameworks and examining the
increased importance in risk assessment and pharmacovigilence in reducing drug bottlenecks
Day Two
Stream One:
Pharmacology: Examining the best practices and optimization strategies in pharmacology and toxicology, including integrated strategies
and best practise case studies
Stream Two:
Translational & Personalised Therapeutics/Partnership and Outsourcing Strategies: Examining emerging areas of personalised medicine
including Omics and patient stratification and exploring partnership and outsourcing strategies in the modern pharmaceutical environment.
WHO YOU WILL MEET
100 senior attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, academics, government, CRO and solution provider companies will be attending. Meet Senior VPs, Directors, and Managers from the following job titles:
Biomarkers Clinical Pharmacology Regulatory Affairs Pharmacogenomics Clinical Research CEO
ADME Translational Medicine Pre-Clinical Research Strategic Alliances Risk Management R&D
Outsourcing Technology Biological Sciences Epigenomics Screening POC Imaging Non-clinical Safety Drug Development Pharmacokinetics Pharma Development Discovery Toxicology Portfolio Strategy PK/PD Surveillance Modelling Bioinformatics
THE NEW EVENT FORMAT: NETWORKING AND BUSINESS MEETING OPPORTUNITIES
Meet the speakers and your peers
In addition to the full conference agenda, this event offers you the chance to meet face-to-face with leading industry solution providers and Senior-level industry peers through a series of formal and informal networking opportunities.
Meet the speakers and delegates through Panel discussions
A selection of our key speakers will be hosting focused discussion groups to drill down into their areas of expertise. Lasting for 30 minutes, each session will start with a brief presentation from the host speaker followed by a panel-led debate.
Meet solution providers
Use our online appointment system to contact solution providers prior to the event and to pre-arrange one-to-one meetings with them. Discuss technologies, services and solutions that address your key business concerns.
THE ORGANISERS
Oxford Global Conferences produces cutting edge congresses and summits in the Life Sciences sector. Focusing on summits,
Conferences and unique congress formats, our success is unrivalled in producing high calibre events that offer tailored
knowledge-sharing, industry solutions and networking opportunities. A list of upcoming events is below:-
5th Annual Biomarkers Congress-25th & 26th February 2010, Midland Hotel, Manchester, UK
2nd Annual Drug Development Congress-22 & 23 April 2010, London
11th Annual Drug Discovery Leaders Summit-9-10 June 2010, Montreux, Switzerland
2nd Annual GPCR Congress-9-10 June 2010, Montreux, Switzerland
Pharma R&D Strategies Congress-26-27 August 2010, Singapore
8th Annual Pharmaceutical Technology IT Summit-4 – 5 October 2010, London
3rd Annual Proteins Congress-28-29 October 2010, Berlin, Germany
Vaccines Congress-28-29 October 2010, Berlin, Germany
2nd Annual qPCR Congress-15-16 November 2010, London, UK
2nd Annual Next Generation Sequencing Congress-15-16 November 2010, London UK
Next Generation Sequencing Congress-29-30 November 2010, Singapore
|
|
|
|
|
|
|
|
Organized by:
|
|
Oxford Global |
|
|
Invited Speakers:
|
|
• David Nicholson, SVP Global Research, Schering Plough
• Wolfgang M. Baiker, Corporate Head of Development, Boehringer Ingelheim
• Philippe Van der Auwera, Global Head of Safety Risk Management & EEA-QPPV , F. Hoffmann-La Roche, AG. Basel, Switzerland
• Jingsong Wang, Director Discovery Medicine & Clinical Pharmacology, Bristol Myers Squibb
• Sophie Banzet, Head of Safety Science CNS, Roche
• Jörg Kemkowski, Vice President, Head of Institute of Pharmacology and Preclinical Drug Safety (IPAS), Nycomed GmbH
• Tino Rossi, VP Preclinical Drug Discovery & Enabling Technologies, Neurosciences CEDD, GSK
• Marc Princivalle, Director of Toxicology, Research and Preclinical Development & Head of Preclinical Risk Assessment, EMEA, Stiefel- a GSK Company
• Thomas Steinbach, Senior Director Safety Surveillance & Risk Management, Wyeth
• Bahija Jallal, VP Translational Sciences, Medimmune
• Thomas Herget, Senior Director R&D New Technology Evaluation Performance & Life Science Chemicals, Merck
• Will Watson, Senior Partnering Director, Teva Innovative Ventures
• Julian C. Matthews, Senior Lecturer in the School of Cancer and Imaging Sciences, University of Manchester
• Elke Persohn, Head of Cellular Imaging Group, Novartis
• Martin Elmlinger, Director Biomarkers, Nycomed
• Agnes Westelinck, Director, Regulatory Affairs, Roche
• Mireille Cantarini, Senior Research Physician in Oncology, AstraZeneca, and Honorary Clinical Fellow in Clinical Genetics, St Marys Hospital, Manchester
• Vicki Ikin, Clinical Biomarker Scientist Group Manager, AstraZeneca
• Lucette Doessegger, Global Head Safety Licensing and Early Development, Roche
• Jean-Pierre Valentin, Director Safety Pharmacology, AstraZeneca
• Roy Mansfield, Director Safety and Risk Management, Pfizer
• Farhad Khan, Principal Scientist in Epidemiology, Novo Nordisk A/S
• Howard Mellor, Pre-Clinical Safety Scientist, General Toxicology Sciences, Safety Assessment UK, AstraZeneca.
• Eugenii Rabiner, Director Clinical Imaging Applications, GSK
• Angela Flannery, Director, R&D Science Policy, AstraZeneca
• Alan Morrison, VP International Regulatory Affairs, Amgen
• James Bailey, GSK Team Leader, Medicinal Chemistry, GSK
• Annick Cauvin, Senior Principal Scientist, Toxicology, UCB
• Gvido Cebers , Principal Scientist, CNSP Research Area Toxicologist, Global Safety Assessment, AstraZeneca
• Michael L. Lim, PharmD, Oncology Medicine Development Centre, GSK
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
Passed
|
|
|
|
|
|
|
|
Registration:
|
|
Registration is still open. Limited spaces still available. Don't miss out on this opportunity. Academic registration £450, Industry Regsitration £650, Vendor registration £1250. Limited time discounts may be available. For more information email at d.morris@oxfordglobal.co.uk or call at +44 (0) 1865 304925
|
|
|
E-mail:
|
|
d.morris@oxfordglobal.co.uk
|
|
|
|
|
|
|
|
|